구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib) Daiichi Sankyo / AstraZeneca·Breast Cancer 124 trials |
|---|---|
Overview Program | Trastuzumab deruxtecan (T-DXd) with pyrotinib |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Technology Payload | deruxtecan (Dato-DXd, Datroway ® )] |
Technology Linker | cleavable peptide linker and a topoisomerase I payload with byst |
MoA Mechanism | targeting hormone receptor |
MoA Biomarker | TROP2 on cancer cell surface and, follow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | interstitial lung disease), with corresponding management strategies |
Clinical Safety signal | interstitial lung disease), with corresponding management strategies |
Clinical Selected reported efficacy | ORR 65.8% |
Clinical Reported ORR | 65.8% |
Clinical Result source | ClinicalTrials.gov NCT04494425 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04494425 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib) Daiichi Sankyo / AstraZeneca·Breast Cancer 124 trials |
|---|---|
Overview Program | Trastuzumab deruxtecan (T-DXd) with pyrotinib |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Technology Payload | deruxtecan (Dato-DXd, Datroway ® )] |
Technology Linker | cleavable peptide linker and a topoisomerase I payload with byst |
MoA Mechanism | targeting hormone receptor |
MoA Biomarker | TROP2 on cancer cell surface and, follow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | interstitial lung disease), with corresponding management strategies |
Clinical Safety signal | interstitial lung disease), with corresponding management strategies |
Clinical Selected reported efficacy | ORR 65.8% |
Clinical Reported ORR | 65.8% |
Clinical Result source | ClinicalTrials.gov NCT04494425 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04494425 |
추천 비교
추천 비교